The Aflac Cancer & Blood Disorders Center has over 130 faculty and nearly 50 Advance Practice Providers (APPs), conducting basic, translational, cooperative group and investigator-initiated clinical research related to pediatric oncology and hematology disorders, with expertise in leukemias, lymphomas, brain tumors, neuroblastoma, sarcomas, rare tumors, renal tumors, CAR T-cell therapies, cancer survivorship, health services research, hemoglobinopathies and hemophilia. Each year our team cares for more than 170 newly diagnosed leukemia and lymphoma patients using a variety of treatment protocols, including blood and marrow transplant (BMT), hematopoietic stem cell transplant, chimeric antigen receptor (CAR)-T therapy, and Phase I and II clinical trials for patients whose cancer has relapsed or is not responding to treatment.